Clinical trials: Metabolic Complication
Type 2 Diabetes Mellitus
A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
The purpose of this study is to evaluate the PK/PD and safety of TA-7284 in patients with type 2 diabetes mellitus who have moderate renal impairment.
- Trial name
- NCT01512849
- Testing
- TA-7284 Low, TA-7284 High
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- Tanabe Pharma Corporation
X-Linked Hypophosphatemia
Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
The primary objectives of the study are to: Establish the safety profile of KRN23 for the treatment of XLH in children between 1 and 4 years old Determine the PD effects of KRN23 treatment on serum phosphorus and other PD markers…
- Trial name
- NCT02750618
- Testing
- Burosumab
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Kyowa Kirin, Inc.
Diabetic Polyneuropathy, Diabetic Foot Ulcer
TempTouch IR Thermometry & Diabetic Patient Self-Care
Foot ulcers develop in diabetics with neuropathy because of cumulative injury over the course of several days. These patients do not feel pain, and do not recognize their foot is being injured until a wound develops.
- Conditions
- Diabetic Polyneuropathy, Diabetic Foot Ulcer, Diabetes, Foot Infection
- Trial name
- NCT00289497
- Testing
- TempTouch®
- Where
- 3 sites in United States
- Volunteers
- 180 people
- Sponsor
- Diabetica Solutions Inc.
Chronic Kidney Disease, Type 1 Diabetes Mellitus
A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
Researchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly, and type 1 diabetes.
- Trial name
- FINE-ONE (NCT05901831)
- Testing
- Finerenone
- Where
- 79 sites in United States, Canada and 7 more
- Volunteers
- 242 people
- Sponsor
- Bayer
Macular Edema
A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease
AURIGA is designed to collect data from routine clinical practice on the effectiveness and utilization of intravitreal aflibercept in the treatment of visual impairment due to diabetic macular edema (DME) or macula edema…
- Trial name
- AURIGA (NCT03161912)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- 11 sites in China, Egypt and 9 more
- Volunteers
- 2,481 people
- Sponsor
- Bayer
Endometrial Cancer
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
- Trial name
- NCT06463028
- Testing
- Sapanisertib, Serabelisib, Paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 40 people
- Sponsor
- Faeth Therapeutics
Hyperphosphatemia, Chronic Kidney Disease
A Study of HS219 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia
This was a study to evaluate the efficacy and safety of HS219, chitosan-loaded chewing gum, when given three times a day for 3 weeks to the hemodialysis (HD) patients with hyperphosphatemia whose serum inorganic phosphorus was…
- Trial name
- NCT01039428
- Testing
- HS219
- Where
- 11 sites in Japan
- Volunteers
- 68 people
- Sponsor
- KDL Inc.
Healthy Subjects, Pharmacokinetics of ASP8232
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease
This study consists of two parts. Part 1 evaluates the effect of renal impairment on the PK and PD of a single dose of ASP8232. In addition, the safety and tolerability will be assessed.
- Conditions
- Healthy Subjects, Pharmacokinetics of ASP8232, Pharmacodynamics of ASP8232, Chronic Kidney Disease (CKD)
- Trial name
- NCT02218099
- Testing
- ASP8232
- Where
- 3 sites in Bulgaria, Moldova and 1 more
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Obesity
Effects of Two Hypocaloric Diets on Weight Loss
The investigators evaluated whether an energy-restricted protein diet with low glycaemic index carbohydrates and soluble fibers (LC-P-LGI) would be more effective than a conventional diet (LC-CONV) on weight-loss and related…
- Trial name
- NCT01312740
- Testing
- LC-P-LGI diet, LC-CONV
- Where
- France
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Ceprodi S.A. Kot
Diabetes Mellitus, Type 2, Renal Disease
A Clinical Trial to Evaluate the Preference Regarding Convenience of Medication and Efficacy/Safety of SUGAMET®XR Tablet 5/1000mg
Multi-center, open-label, single arm study to Evaluate the preference regarding convenience of medication, efficacy and safety of Sugamet XR tab. 5/1000mg in patients with Type 2 diabetes and renal diseases
- Conditions
- Diabetes Mellitus, Type 2, Renal Disease, Diabetes Mellitus, Metabolic Disease
- Trial name
- NCT04653779
- Testing
- Evogliptin 5mg/Metformin 1000mg
- Where
- 2 sites in South Korea
- Volunteers
- 54 people
- Sponsor
- Dong-A ST Co., Ltd.
Fabry Disease
A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects with Fabry Disease and Amenable GLA Variants and Severe Renal Impairment (SRI) or End Stage Renal Disease (ESRD)
- Trial name
- NCT04020055
- Testing
- migalastat HCl 150 mg
- Where
- 12 sites in United States, Australia and 4 more
- Volunteers
- 14 people
- Sponsor
- Amicus Therapeutics
Iron Deficiency Anemia, Iron Deficiency Anaemia
An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
Evaluate safety and efficacy of intravenous (IV) iron isomaltoside/ferric derisomaltose re-dosing, in subjects who were previously treated with iron isomaltoside/ferric derisomaltose.
- Trial name
- FERWON-EXT (NCT02962648)
- Testing
- Iron isomaltoside/ferric derisomaltose
- Where
- 22 sites in United States
- Volunteers
- 103 people
- Sponsor
- Pharmacosmos A/S
Chronic Kidney Disease, Renal Insufficiency
A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis
This is a randomized, double blind, placebo-controlled multi-center study to examine the efficacy and safety of ASP1585 in chronic kidney disease patients with hyperphosphatemia not on dialysis.
- Conditions
- Chronic Kidney Disease, Renal Insufficiency, Hyperphosphatemia
- Trial name
- NCT01742585
- Testing
- ASP1585
- Where
- 5 sites in Japan
- Volunteers
- 163 people
- Sponsor
- Astellas Pharma Inc
Heart Failure, Edema
Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure
The primary objective of this study is to learn whether a morning dose of extended-release torsemide enhances renal sodium excretion after lunch (4-8 hours after dosing) compared to immediate-release torsemide.
- Conditions
- Heart Failure, Edema, Pulmonary Congestion, Fluid Overload
- Trial name
- NEXT-HF (NCT06995144)
- Testing
- Extended Release Torsemide Tablets, Immedate Release Torsemide Tablets
- Where
- United States
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Insulin Dependent Diabetes, Non Insulin Dependent Diabetes
Evaluation and Comparison of Noninvasive Blood Glucose Concentrations
Comparison of noninvasive glucose measurement performance versus standard invasive reference measurements.
- Conditions
- Insulin Dependent Diabetes, Non Insulin Dependent Diabetes, Gestational Diabetes
- Trial name
- NCT01745900
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- VeraLight, Inc.
Hyperphosphataemia, ESRD
Non-interventional Study to Evaluate the Ease of Reaching Individual Goals in Serum Phosphorus (Steering)
The objective of this non-interventional study is to confirm that with standard OsvaRen® treatment it is possible to achieve in at least 60% of the patients the levels of phosphorus, total calcium, and iPTH seen in the CALMAG…
- Trial name
- Steering (NCT01424787)
- Where
- 24 sites in Denmark, Germany and 2 more
- Volunteers
- 324 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Renal Insufficiency, Chronic
Short-term Metabolic Effects of Ketosteril® Supplemented Low Protein Diet in Pre-dialysis Chronic Kidney Disease (CKD) Patients
Supplementation of ketoanalogues of essential amino acids improves the protein quality of protein restricted diets without burdening the kidneys.
- Trial name
- CKD (NCT03077048)
- Testing
- Ketosteril®
- Where
- Czechia
- Volunteers
- 23 people
- Sponsor
- Fresenius Kabi
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study to Learn More About Chronic Kidney Disease (CKD) in Patients With Type 2 Diabetes Mellitus (T2DM)
In this observational study, data from the recent past of patients with type 2 diabetes mellitus and chronic kidney disease will be studied.
- Trial name
- CKD-T2DM (NCT05004428)
- Testing
- No intervention
- Where
- Canada
- Volunteers
- 336,376 people
- Sponsor
- Bayer
Short Bowel Syndrome (SBS)
Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
The purpose of this study is to understand the safety and efficacy of twice weekly glepaglutide 10 mg in adult patients with short bowel syndrome (SBS), who were previously enrolled in the EASE SBS 2 or EASE SBS 3 trials.
- Trial name
- EASE SBS 6 (NCT07228403)
- Testing
- Glepaglutide 10 mg
- Where
- 16 sites in United States, Belgium and 5 more
- Volunteers
- 28 people
- Sponsor
- Zealand Pharma
Type 2 Diabetes Mellitus, Diabetic Nephropathy
Olmesartan Medoxomil and Diabetic Nephropathy
Evaluation of several olmesartan dosages compared to losartan on proteinuria, renal function and inflammatory markers in patients with diabetic nephropathy
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Nephropathy, Proteinuria, Renal Disease
- Trial name
- NCT00362960
- Testing
- Olmesartan medoxomil, Losartan
- Where
- 27 sites in Czechia, Estonia and 5 more
- Volunteers
- 300 people
- Sponsor
- Sankyo Pharma Gmbh